Consensus NovoCure Limited

Stocks

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-11-11 EST			5-day change	1st Jan Change
11.99 ^USD	+1.52%		-17.93%	-7.27%

11-09	Novocure Provides Regulatory Update On U.S. FDA Premarket Approval Application For Optune Mya For Brain Metastases From Non-Small Cell Lung Cancer	CI
11-09	Novocure Receives FDA Rejection for Tumor Device Application	MT

Evolution of the Average Target: NovoCure Limited

Evolution of the Target Price: NovoCure Limited

Changes in Analyst Recommendations: NovoCure Limited

9d30ea8b9a9310947.sD6FE3Dzbm5aB-fIYUC9eYmQWzjKZVSAGGNB3Kz5x30.4FjDXBe8Kg0bWNe5JC32MePnFneZUR6xWzB06JqTvg_nZsJAR7UoKmxpqg~974db7981f05a63b2e72f99be89f2b53

Analysts' recommendations: NovoCure Limited

11-09	Wedbush Trims Price Target on NovoCure to $19 From $20, Keeps Neutral Rating	MT
07-24	Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating	MT
25-07-25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
25-07-25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
25-07-24	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT
25-07-08	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
24-12-02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
24-12-02	Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	MT
24-12-02	Evercore ISI Upgrades NovoCure to Outperform	MT
24-10-16	HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	MT
24-06-04	Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	MT
24-04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT
24-04-03	Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	MT
24-02-23	Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	MT
23-10-26	Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	MT
23-08-29	Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	MT
23-08-28	HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	MT
23-08-28	Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	MT
23-08-08	Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	MT
23-08-04	SVB Securities Initiates NovoCure at Outperform With $51 Price Target	MT
23-07-31	Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
23-06-07	Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	MT

More recommendations

Medical Equipment

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NOVOCURE LIMITED					+116.52%
	ABBOTT LABORATORIES					+7.65%
	MEDTRONIC PLC					+3.36%
	STRYKER CORPORATION					+4.37%
	ESSILORLUXOTTICA					+15.09%
	CENCORA, INC.					+9.33%
	BECTON, DICKINSON AND COMPANY					+6.37%
	IDEXX LABORATORIES, INC.					+2.95%
	HOYA CORPORATION					+29.96%
	ALCON INC.					+20.14%
	Average					+21.57%
	Weighted average by Cap.					+9.21%